Pharmacogenetics of oral antidiabetic therapy-Reference-Cited by-同舟云学术

Pharmacogenetics of oral antidiabetic therapy

Published:2018-04 Issue:6 Volume:19 Page:577-587
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Ordelheide Anna-Maria¹²,Hrabě de Angelis Martin²³⁴,Häring Hans-Ulrich¹²⁵⁶,Staiger Harald¹²⁶⁷

Affiliation:

1. Institute for Diabetes Research & Metabolic Diseases of the Helmholtz Centre Munich at the Eberhard Karls University Tübingen, Germany

2. German Center for Diabetes Research (DZD), Neuherberg, Germany

3. Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany

4. Chair for Experimental Genetics, Technical University Munich, Neuherberg, Germany

5. Department of Internal Medicine IV, Division of Endocrinology, Diabetology, Angiology, Nephrology & Clinical Chemistry, University Hospital Tübingen, Germany

6. Interfaculty Center for Pharmacogenomics & PharmaResearch at the Eberhard Karls University Tübingen, Germany

7. Institute of Pharmaceutical Sciences, Department of Pharmacy & Biochemistry, Eberhard Karls University Tübingen, Germany

Abstract

Type 2 diabetes prevalence is still on the rise worldwide. Antidiabetic drugs are widely prescribed to patients with Type 2 diabetes. Most patients start with metformin which is mostly well tolerated. However, a high percentage of patients fail to achieve glycemic control. The effectiveness of metformin as well as most other antidiabetic drugs depends among other factors on interindividual genetic differences that are up to now ignored in the treatment of Type 2 diabetes. Interestingly, many genes influencing the effectiveness of antidiabetic drugs are Type 2 diabetes risk genes making matters worse. Here, we shed light on these interindividual genetic differences.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2017-0195

Reference101 articles.

1. Beta Cell Dysfunction and Insulin Resistance

2. Type 2 diabetes detection and management among insured adults

3. IDF Diabetes Atlas – 7th Edition. www.diabetesatlas.org.

4. The genetics of type 2 diabetes: what have we learned from GWAS?

5. Analysis of Separate and Combined Effects of Common Variation in KCNJ11 and PPARG on Risk of Type 2 Diabetes

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic diversity of variants involved in drug response among Tunisian and Italian populations toward personalized medicine;Scientific Reports;2024-03-10

2. Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects;Frontiers in Endocrinology;2023-03-15

3. Association of SLC22A1, SLC47A1, and KCNJ11 polymorphisms with efficacy and safety of metformin and sulfonylurea combination therapy in Egyptian patients with type 2 diabetes;Research in Pharmaceutical Sciences;2023

4. Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus;Frontiers in Endocrinology;2022-08-16

5. Variants of SLC2A10 may be Linked to Poor Response to Metformin;Journal of the Endocrine Society;2022-06-29